FLUIDIGM CORP Uncategorized Contracts & Agreements

Offer letter, by and between Standard BioTools Inc. and Jeremy Davis, dated April 4, 2023 (Filed With SEC on August 8, 2023)

Form of PSU Award Agreement (Filed With SEC on July 28, 2023)

Offer letter by and between Standard BioTools Inc. and Jeffery G. Black executed May 10, 2023 (Filed With SEC on May 15, 2023)

Letter agreement by and between Standard BioTools Inc. and Vikram Jog dated May 10, 2023 (Filed With SEC on May 15, 2023)

Support Agreement, dated March 29, 2022, by and among Fluidigm Corporation and Caligan Partners LP and certain of its affiliates (Filed With SEC on March 29, 2022)

Letter Agreement dated March 25, 2022 (Filed With SEC on March 28, 2022)

Michael Egholm Offer Letter (Filed With SEC on January 24, 2022)

Hanjoon Alex Kim Offer Letter (Filed With SEC on January 24, 2022)

Amendment dated (Filed With SEC on November 9, 2021)

Amendment dated May 10, 2021 to (Filed With SEC on August 6, 2021)

Repatriation Agreement with Colin McCracken dated June 16, 2021 (Filed With SEC on August 6, 2021)

Contract by and between the National Institutes of Health and the registrant effective as of July 30, 2020, as amended September 28, 2020 (Filed With SEC on May 7, 2021)

Description of Securities (Filed With SEC on February 25, 2021)

Offer Letter to Colin McCracken dated April 12, 2019 (Filed With SEC on February 25, 2021)

Offer Letter to Nick Khadder dated April 6, 2020 (Filed With SEC on February 25, 2021)

Contract by and between the National Institutes of Health and the (Filed With SEC on November 9, 2020)

Letter Agreement between President and Fellows of Harvard College and the registrant dated December 22, 2004 (Filed With SEC on November 9, 2020)

Open Market Sale AgreementSM, dated as of March 4, 2020, between Fluidigm Corporation and Jefferies LLC (Filed With SEC on March 5, 2020)

Description of Securities (Filed With SEC on February 27, 2020)

Offer Letter to Bradley A. Kreger dated February 13, 2018 (Filed With SEC on March 18, 2019)

Offer Letter to Chris Linthwaite, dated as of July 14, 2016 (Filed With SEC on May 8, 2018)

Endorsement Split-Dollar Life Insurance Agreement (Filed With SEC on November 7, 2017)

FLUIDIGM CORPORATION 2017 INDUCEMENT AWARD PLAN (Filed With SEC on January 11, 2017)

TAX BENEFIT PRESERVATION PLAN Dated as of November 21, 2016 by and between FLUIDIGM CORPORATION and COMPUTERSHAREINC., as Rights Agent TABLE OF CONTENTS (Filed With SEC on November 22, 2016)

CONFIDENTIAL TREATMENT REQUESTED (Filed With SEC on November 9, 2016)

ascendas.com (Filed With SEC on August 10, 2015)

SUBLICENSE AGREEMENT (Filed With SEC on May 12, 2014)

Monthly Service Charge (Filed With SEC on March 12, 2014)

FluidigmCorporation 7000 Shoreline Court, Suite 100, South San Francisco, California 94080 tel:650.266.6000 fax: 650.871.7152 www.fluidigm.com (Filed With SEC on April 4, 2011)

CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION LICENSEAGREEMENT by and between NOVARTIS VACCINES & DIAGNOSTICS, INC. and FLUIDIGM CORPORATION DATE: [ ] (Filed With SEC on February 2, 2011)

COLLABORATIONAND OPTION AGREEMENT by and between NOVARTIS VACCINES & DIAGNOSTICS, INC. and FLUIDIGM CORPORATION DATE: MAY 17, 2010 (Filed With SEC on January 18, 2011)

LICENSEAGREEMENT by and between NOVARTIS VACCINES & DIAGNOSTICS, INC. and FLUIDIGM CORPORATION Date: [ ] (Filed With SEC on January 18, 2011)

FLUIDIGM CORPORATION and 454 LIFE SCIENCES, A ROCHE COMPANY CO-PROMOTION AGREEMENT (Filed With SEC on January 18, 2011)

5,300,000 SHARES (Filed With SEC on September 15, 2008)

Shares (Filed With SEC on September 15, 2008)

FLUIDIGM CORPORATION (Filed With SEC on September 15, 2008)

Fluidigm Corporation a California corporation (Filed With SEC on September 15, 2008)

MASTER CLOSING AGREEMENT By and Among FLUIDIGM CORPORATION, a California corporation, OCULUS PHARMACEUTICALS, INC., a Delaware corporation, and THE UAB RESEARCH FOUNDATION dated... (Filed With SEC on September 15, 2008)

PROJECT MILESTONES AND DELIVERABLES (Filed With SEC on September 15, 2008)

EXHIBIT 10.3A (Filed With SEC on September 5, 2008)